Genetics in Anti-Platelet Treatment

被引:2
作者
Gazouli, Maria [1 ]
机构
[1] Natl & Kapodistrian Univ Athens, Sch Med, Dept Basic Med Sci, Biol Lab, Athens, Greece
关键词
Anti-platelet therapy; aspirin; ticagrelor; prasugrel; clopidogrel; GPIIb/IIIa inhibitors; acute coronary syndromes; cardiovascular disease; gene polymorphisms; miRNAs; CORONARY-ARTERY-DISEASE; TREATMENT PLATELET REACTIVITY; CYP2C19; GENOTYPE; CLOPIDOGREL RESPONSIVENESS; CARDIOVASCULAR EVENTS; ENDOTHELIAL FUNCTION; ASPIRIN RESISTANCE; MAJOR DETERMINANT; POLYMORPHISMS; THERAPY;
D O I
10.2174/1381612822666160601105058
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Anti-platelet drugs are necessary in treating patients with coronary artery disease, ischemic stroke and peripheral arterial disease. However, despite the use of adequate anti-platelet therapy, some patients will experience a recurrent atherothrombotic vascular event. These patients are characterized as low- or non-responders to therapy. Individual responsiveness to anti-platelet therapy as the use of clopidogrel and/or aspirin varies widely among patients. Such an individual variability is mainly determined by environmental and genetic factors. In this review, we focused on the underlying genetic mechanisms that might influence response to anti-platelet drugs.
引用
收藏
页码:4506 / 4511
页数:6
相关论文
共 63 条
[1]   The GPIIIa PlA polymorphism and the platelet hyperactivity in Tunisian patients with stable coronary artery disease treated with aspirin [J].
Abderrazek, Fatma ;
Chakroun, Tahar ;
Addad, Faouzi ;
Dridi, Zohra ;
Gerotziafas, Grigoris ;
Gamra, Habib ;
Hassine, Mohsen ;
Elalamy, Ismail .
THROMBOSIS RESEARCH, 2010, 125 (06) :E265-E268
[2]   The contribution of platelet glycoproteins (GPIa C807T and GPIba C-5T) and cyclooxygenase 2 (COX-2G-765C) polymorphisms to platelet response in patients treated with aspirin [J].
Al-Azzam, Sayer I. ;
Alzoubi, Karem H. ;
Khabour, Omar F. ;
Tawalbeh, Deniz ;
Al-Azzeh, Ola .
GENE, 2013, 526 (02) :118-121
[3]   Impact of Genetic Polymorphisms and Drug-Drug Interactions on Clopidogrel and Prasugrel Response Variability [J].
Ancrenaz, V. ;
Daali, Y. ;
Fontana, P. ;
Besson, M. ;
Samer, C. ;
Dayer, P. ;
Desmeules, J. .
CURRENT DRUG METABOLISM, 2010, 11 (08) :667-677
[4]  
[Anonymous], SAF FUDAFD PLAV CREO
[5]  
[Anonymous], PLOS CURR
[6]   Measurement of platelet reactivity of patients with cardiovascular disease on-treatment with acetyl salicylic acid: a prospective study [J].
Awidi, Abdalla ;
Saleh, Akram ;
Dweik, Manar ;
Kailani, Baraah ;
Abu-Fara, Mohammed ;
Nabulsi, Rinad ;
Bener, Abdulbari .
HEART AND VESSELS, 2011, 26 (05) :516-522
[7]   Relationship between post-treatment platelet reactivity and ischemic and bleeding events at 1-year follow-up in patients receiving prasugrel [J].
Bonello, L. ;
Mancini, J. ;
Pansieri, M. ;
Maillard, L. ;
Rossi, P. ;
Collet, F. ;
Jouve, B. ;
Wittenberg, O. ;
Laine, M. ;
Michelet, P. ;
Bessereau, J. ;
Lemesle, G. ;
Dignat-George, F. ;
Paganelli, F. ;
Camoin-Jau, L. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2012, 10 (10) :1999-2005
[8]   Paraoxonase-1 is a major determinant of clopidogrel efficacy [J].
Bouman, Heleen J. ;
Schoemig, Edgar ;
van Werkum, Jochem W. ;
Velder, Janna ;
Hackeng, Christian M. ;
Hirschhaeuser, Christoph ;
Waldmann, Christopher ;
Schmalz, Hans-Guenther ;
ten Berg, Jurrien M. ;
Taubert, Dirk .
NATURE MEDICINE, 2011, 17 (01) :110-U287
[9]   Frequency of CYP3A4, CYP3A5, CYP2C9, and CYP2C19 variant alleles in patients receiving clopidogrel that experience repeat acute coronary syndrome [J].
Brackbill, Marcia L. ;
Kidd, Robert S. ;
Abdoo, April D. ;
Warner, James G., Jr. ;
Harralson, Arthur F. .
HEART AND VESSELS, 2009, 24 (02) :73-78
[10]   Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel [J].
Brandt, J. T. ;
Close, S. L. ;
Iturria, S. J. ;
Payne, C. D. ;
Farid, N. A. ;
Ernest, C. S., II ;
Lachno, D. R. ;
Salazar, D. ;
Winters, K. J. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2007, 5 (12) :2429-2436